keyword
MENU ▼
Read by QxMD icon Read
search

Ozurdex

keyword
https://www.readbyqxmd.com/read/29662300/the-effects-of-repeated-ozurdex-injections-on-ocular-hypertension
#1
Sepehr Bahadorani, Chelsey Krambeer, Kendall Wannamaker, Wayne Tie, Michael Jansen, Jason Espitia, Jeong-Hyeon Sohn, Michael A Singer
Purpose: The purpose of this study was to correlate the degree of ocular hypertension with the number of Ozurdex injections. Methods: Intraocular pressure (IOP) fluctuations for a total of 183 injections were studied over a period of at least 12 months. The main indications for treatment were uveitis, diabetic macular edema, and retinal vein occlusion. Results: Results of the study demonstrate that repeated Ozurdex injections do not increase the frequency of IOP spikes beyond 30 mmHg...
2018: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29643797/uneventful-anterior-migration-of-intravitreal-ozurdex-implant-in-a-patient-with-iris-sutured-intraocular-lens-and-descemet-stripping-automated-endothelial-keratoplasty
#2
Andleeb Zafar, Ioannis M Aslanides, Vasileios Selimis, Konstantinos I Tsoulnaras, David Tabibian, George D Kymionis
Purpose: We report here the case of a patient with anterior segment migration of intravitreal dexamethasone implant as well as its management and outcome. Methods: The patient had the following sequence of events: complicated cataract surgery, iris-sutured intraocular lens implant, followed by cystoid macular edema treated with intravitreal Avastin, retinal vein occlusion treated with intravitreal dexamethasone implant, corneal decompensation treated with Descemet stripping automated endothelial keratoplasty (DSAEK), and finally recurrence of macular edema treated with repeated intravitreal dexamethasone implant...
January 2018: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/29617689/clinical-decision-making-when-treating-diabetic-macular-edema-patients-with-dexamethasone-intravitreal-implants
#3
Alfredo García-Layana, Marta S Figueroa, Luis Arias, Alfredo Adán, Francisco Cabrera, Maximino Abraldes, Álvaro Fernández-Vega, Rafael Navarro, Enrique Cervera, Rufino Silva, Felix Armadá, Juan Donate, José Maria Ruiz-Moreno
Diabetes mellitus (DM) is a metabolic disease frequently associated with comorbidities that include diabetic macular edema (DME). The current medical approach to treating DME involves intravitreal injections with either anti-vascular endothelial growth factors or steroids. However, the burden associated with intravitreal injections and DM-derived complications is high, underlining the need to find optimal treatment regimens. In this article we describe the considerations we apply when treating DME patients with dexamethasone intravitreal implants (Ozurdex®), particularly those that influence the clinical decision-making process during the follow-up period...
April 4, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29515431/intralenticular-ozurdex%C3%A2-one-year-later
#4
Kathleen A Regan, Charles R Blake, Zachary L Lukowski, Siva S R Iyer
Reported here is a case of intralenticular sustained-release dexamethasone implant (Ozurdex®, Allergan, Irvine, CA, USA) present for 1 year with effective treatment of refractory diabetic macular edema without rapid cataract formation. The crystalline lens remained stable for 12 months on exam despite the presence of the steroid-secreting foreign body. The diabetic macular edema resolved on exam and on optical coherence tomography. After 1 year, cataract extraction was uneventfully performed by phacoemulsification for a mild decline in visual acuity...
September 2017: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/29505751/dexamethasone-intravitreal-implant-downregulates-pdgfr-%C3%AE-and-upregulates-caveolin-1-in-experimental-branch-retinal-vein-occlusion
#5
Lasse Jørgensen Cehofski, Anders Kruse, Sigriður Olga Magnusdottir, Alexander Nørgård Alsing, Svend Kirkeby, Bent Honoré, Henrik Vorum
A dexamethasone intravitreal implant (OZURDEX) provides an effective treatment of inflammation secondary to branch retinal vein occlusion (BRVO). Retinal proteome changes which mediate the beneficial effects of the implant remain poorly understood. To study retinal proteome changes in BRVO following an intervention with a dexamethasone (DEX) implant this study combined an experimental model of BRVO with proteomic techniques. In six Danish Landrace pigs experimental BRVO was induced in both eyes using argon laser...
March 2, 2018: Experimental Eye Research
https://www.readbyqxmd.com/read/29490233/influence-of-the-test-method-on-in-vitro-drug-release-from-intravitreal-model-implants-containing-dexamethasone-or-fluorescein-sodium-in-poly-d-l-lactide-co-glycolide-or-polycaprolactone
#6
Sandra Stein, Tobias Auel, Wiebke Kempin, Malte Bogdahn, Werner Weitschies, Anne Seidlitz
Sustained intravitreal dexamethasone (DX) administration with the FDA and EMA approved Ozurdex® implant is indicated for the treatment of macular edema and non-infectious uveitis. Since drug release after intravitreal application cannot be determined in vivo in human eyes, the characterization of drug release in vitro in addition to animal models is of great importance. The aim of this study was to provide information about the influence of the test method on the in vitro drug release from intravitreal model implants...
February 25, 2018: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/29485235/extension-of-peripheral-nonperfusion-in-eyes-with-retinal-vein-occlusion-during-intravitreal-dexamethasone-treatment
#7
Sandra Rezar-Dreindl, Katharina Eibenberger, Wolf Buehl, Günther Weigert, Michael Georgopoulos, Ursula Schmidt-Erfurth, Stefan Sacu
BACKGROUND: To evaluate the change in peripheral perfusion status in patients with retinal vein occlusion (RVO) during dexamethasone treatment. METHODS: Thirty-five eyes of patients with macular oedema due to either branch or central retinal vein occlusion were included. At baseline, patients were treated with an intravitreal dexamethasone implant (Ozurdex® ) and followed until month 6. Wide-field angiographies were classified as ischaemic and nonischaemic. Peripheral nonperfusion (PNP) was determined manually by calculating the percentage of nonperfusion area in relation to the total visible retina (ischaemic index)...
February 27, 2018: Acta Ophthalmologica
https://www.readbyqxmd.com/read/29459041/dexamethasone-inserts-in-noninfectious-uveitis-a-single-center-experience
#8
Dominika Pohlmann, Gerrit A Vom Brocke, Sibylle Winterhalter, Theresa Steurer, Sabrina Thees, Uwe Pleyer
PURPOSE: To report the effectiveness of repeated intravitreal dexamethasone (DEX) inserts in noninfectious uveitis patients. DESIGN: Prospective, single-center, interventional clinical trial between February 2010 and March 2015. PARTICIPANTS: Patients with noninfectious uveitis with cystoid macular edema and/or vitreitis. METHODS: Patients were treated with a 700-μg intravitreal DEX insert (Ozurdex; Allergan, Inc., Irvine, CA)...
February 16, 2018: Ophthalmology
https://www.readbyqxmd.com/read/29452450/-cost-comparison-of-licensed-intravitreal-therapies-for-insufficiently-anti-vegf-responding-fovea-involving-diabetic-macular-edema-in-germany
#9
Aljoscha S Neubauer, Christos Haritoglou, Michael W Ulbig
BACKGROUND: In the treatment of center-involving diabetic macular edema, despite initial therapy with an anti-VEGF compound, an insufficient response may occur. Further therapy options include a switch of anti-VEGF products or to corticosteroid implants, such as Fluocinolone acetonide or Dexamethasone. OBJECTIVES: Firstly, to investigate systematically which evidence-based study data are available describing the efficacy of in-label treatments after primary anti-VEGF treatment, secondly, to investigate which costs go along for the healthcare provider...
February 16, 2018: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29403585/effects-of-dexamethasone-implant-on-multifocal-electroretinography-in-central-retinal-vein-occlusion
#10
Muhammed Nurullah Bulut, Ümit Çallı, Güzide Akçay, Ulviye Kıvrak, Kezban Bulut, Yusuf Özertürk
Purpose: To investigate the effect of Ozurdex (dexamethasone intravitreal implant) on multifocal electroretinography (mfERG) findings during the treatment of macular edema secondary to the central retinal vein occlusion (CRVO). Methods: Fifteen eyes of 15 patients who were treated with Ozurdex implant due to CRVO-related macular edema were included in this study. Best corrected visual acuity (BCVA), central macular thickness (CMT), and mfERG evaluations were performed for all patients before injection of Ozurdex...
January 2018: Journal of Ophthalmic & Vision Research
https://www.readbyqxmd.com/read/29380183/intravitreal-dexamethasone-implant-with-retinal-photocoagulation-for-adult-onset-coats-disease
#11
Kshitiz Kumar, Pallavi Raj, Nisha Chandnani, Amar Agarwal
PURPOSE: To report a case of adult-onset Coats' disease with secondary retinal vasoproliferative tumor managed with dexamethasone intravitreal implant and retinal photocoagulation. METHODS: Case study. RESULTS: A 41-year-old female with counting finger vision was diagnosed with Coats' disease with secondary retinal vasoproliferative tumor in right eye. Fundus examination revealed exudative retinopathy involving posterior pole and a retinal tumor located in the inferotemporal quadrant...
January 29, 2018: International Ophthalmology
https://www.readbyqxmd.com/read/29376223/bevacizumab-versus-dexamethasone-implant-followed-by-bevacizumab-for-the-treatment-of-macula-edema-associated-with-branch-retinal-vein-occlusion
#12
Su Young Moon, Kwan Hyuk Cho, Se Joon Woo, Sung Pyo Park, Yong Kyu Kim
PURPOSE: To compare visual and anatomical outcomes of intravitreal injections of bevacizumab and dexamethasone implant (Ozurdex) treatment for macular edema associated with branch retinal vein occlusion (BRVO). METHODS: We retrospectively reviewed patients who underwent intravitreal bevacizumab administered monthly on a pro re nata (PRN) basis (26 eyes, IVB group) or an initial 700-μg dexamethasone implant followed by a bevacizumab PRN injection (20 eyes, IVD group) for treatment of macular edema associated with BRVO...
February 2018: Korean Journal of Ophthalmology: KJO
https://www.readbyqxmd.com/read/29352994/topical-drug-delivery-devices-a-review
#13
REVIEW
Christian J F Bertens, Marlies Gijs, Frank J H M van den Biggelaar, Rudy M M A Nuijts
For the treatment and prevention of ocular diseases, most patients are treated with conventional drug delivery formulations such as eye drops or ointments. However, eye drops and ointments suffer from low patient compliance and low effective drug concentration at the target site. Therefore, new medical devices are being explored to improve drug delivery to the eye. Over the years, various delivery devices have been developed including resorbable devices, oval- and ring-shaped devices, rod-shaped devices, punctum plugs, contact lenses and corneal shields...
March 2018: Experimental Eye Research
https://www.readbyqxmd.com/read/29304271/blau-jabs-syndrome-in-a-tertiary-ophthalmologic-center
#14
Heloisa Nascimento, Jacqueline M Sousa, Délia González Fernández, Gustavo H A Salomão, Elcio H Sato, Cristina Muccioli, Rubens Belfort
In a prospective case series of patients with Blau-Jabs syndrome (BJS) conducted in the Ophthalmology Department/Federal University of Sao Paulo, seven patients with clinical and ophthalmologic manifestations of the disease and a positive genetic test result for the presence of a mutation in the CARD15/NOD2 gene were followed for a minimal period of 1 year. All patients had uveitis, five had nummular corneal subepithelial opacities, and four had multifocal choroiditis. Oral prednisolone was administered to all patients; inflammation was controlled in six patients with at least one immunosuppressive drug...
January 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29260111/corneal-graft-failure-due-to-migration-of-ozurdex%C3%A2-implant-into-the-anterior-chamber
#15
Haifa A Madi, Stephen J Morgan, Saurabh Ghosh
Purpose: We report a case of corneal endothelial graft failure secondary to dexamethasone intravitreal implant (Ozurdex™) migration into the anterior chamber (AC). Observations: A 53-year-old man with a history of bilateral idiopathic chronic uveitis, had a right anterior vitrectomy and AC intraocular lens (ACIOL) with a peripheral iridotomy. He received an intravitreal Ozurdex™ implant for right cystoid macular oedema (CMO). Three months later he developed pseudophakic bullous keratopathy and underwent a Descemet stripping automated endothelial keratoplasty (DSAEK), combined with IOL exchange (ACIOL explantation followed by scleral fixated posterior chamber IOL)...
December 2017: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29207977/acute-zonal-occult-outer-retinopathy-azoor-a-case-report-of-vision-improvement-after-intravitreal-injection-of-ozurdex
#16
Yi Chun Kuo, Nancy Chen, Rong Kung Tsai
BACKGROUND: AZOOR was first described by Gass in 1993 as a syndrome with rapid loss of one or more extensive zones of the outer retinal segments. It is characterized by photopsia, minimal funduscopic changes, and electroretinographic abnormalities. The efficacy of systemic steroids in treating AZOOR has been previously described and advocated by the concept of autoimmune retinopathy. However, the use of intravitreal of sustained-released steroid had not been mentioned to date. CASE PRESENTATION: A 34-year-old man had sudden onset of central scotoma and photopsia in the left eye...
December 6, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/29192395/intracrystalline-ozurdex-%C3%A2-therapeutic-effect-maintained-for-18-months
#17
Rodrigo Clemente-Tomás, Delia Hernández-Pérez, Paulina Neira-Ibáñez, Francisco Farías-Rozas, Raúl Torrecillas-Picazo, Vanesa Osorio-Alayo, Antonio M Duch-Samper
INTRODUCTION: Ozurdex® is a sterile, sustained-release implant of dexamethasone. The device dissolves within the vitreous body and releases dexamethasone. Here we present a clinical case that demonstrates the sustained therapeutic efficacy of Ozurdex® when accidentally injected into the crystalline lens. METHODS: Case report. RESULTS: Sixty-three-year-old male in which we decided to prescribe the intravitreal injection of a dexamethasone implant (Ozurdex® ) in the left eye because of macular oedema after branch retinal vein occlusion...
November 30, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/29183563/a-systematic-review-and-economic-evaluation-of-adalimumab-and-dexamethasone-for-treating-non-infectious-intermediate-uveitis-posterior-uveitis-or-panuveitis-in-adults
#18
Hazel Squires, Edith Poku, Inigo Bermejo, Katy Cooper, John Stevens, Jean Hamilton, Ruth Wong, Alastair Denniston, Ian Pearce, Fahd Quhill
BACKGROUND: Non-infectious intermediate uveitis, posterior uveitis and panuveitis are a heterogeneous group of inflammatory eye disorders. Management includes local and systemic corticosteroids, immunosuppressants and biological drugs. OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of subcutaneous adalimumab (Humira® ; AbbVie Ltd, Maidenhead, UK) and a dexamethasone intravitreal implant (Ozurdex® ; Allergan Ltd, Marlow, UK) in adults with non-infectious intermediate uveitis, posterior uveitis or panuveitis...
November 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/29155696/safety-of-consecutive-same-day-bilateral-intravitreal-dexamethasone-implant-ozurdex
#19
Kapil G Kapoor, James B Colchao
PURPOSE: The objective of this study was to evaluate patient safety and tolerance of consecutive bilateral intravitreal dexamethasone (Ozurdex) injections during a single visit for the treatment of cystoid macular edema secondary to retinal vein occlusion, diabetic macular edema, or noninfectious posterior uveitis. METHODS: This was a retrospective single-center institutional review board-approved study from March 1, 2013, through August 1, 2016. All patients had a complete ophthalmologic examination and optical coherence tomography imaging...
November 16, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/29119239/safety-and-efficacy-of-dexamethasone-intravitreal-implant-for-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-chinese-patients-randomized-sham-controlled-multicenter-study
#20
RANDOMIZED CONTROLLED TRIAL
Xiaoxin Li, Ningli Wang, Xiaoling Liang, Gezhi Xu, Xiao-Yan Li, Jenny Jiao, Jean Lou, Yehia Hashad
PURPOSE: The purpose of this study was to evaluate the safety and efficacy of dexamethasone intravitreal implant 0.7 mg (DEX) for treatment of macular edema associated with retinal vein occlusion (RVO). METHODS: This study was a six-month, randomized, double-masked, sham-controlled, multicenter, phase 3 clinical trial with a 2-month open-label study extension. Patients with branch or central RVO received DEX (n = 129) or sham procedure (n = 130) in the study eye at baseline; all patients who met re-treatment criteria received DEX at month 6...
January 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
keyword
keyword
33543
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"